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An oseltamivir-resistant inﬂ  uenza A pandemic (H1N1) 
2009 virus evolved and emerged from zero to 52% of de-
tectable virus within 48 hours of a patient’s exposure to 
oseltamivir. Phylogenetic analysis and data gathered by 
pyrosequencing and cloning directly on clinical samples 
suggest that the mutant emerged de novo.
E
arly descriptions of emergence of H275Y mutants in 
pandemic (H1N1) 2009 virus showed resistance after 
11 and 23 days of therapy in immunosuppressed patients 
(1). Also in previous reports, transmission of mutant vi-
ruses occurred in immunosuppressed patients (2), although 
a cluster among healthy persons demonstrated that H275Y 
mutants could replicate and cause disease in the absence 
of drug pressure (3). Additional reports noted decreasing 
times to detection of resistance, from 14 to 4 days after 
therapy (4–6). We report development of oseltamivir-resis-
tant pandemic (H1N1) 2009 virus in an infected woman in 
Singapore within 48 hours of drug treatment.
The Study 
Pandemic (H1N1) 2009 virus was ﬁ   rst detected in 
Singapore in May 2009. Infected patients were placed in 
isolation and offered oseltamivir, and respiratory samples 
were collected for screening for H275Y, the principal mu-
tation associated with oseltamivir resistance in inﬂ  uenza A 
N1 viruses. H275Y was detected in a pandemic (H1N1) 
2009 virus isolated from a sample from a 28-year-old fe-
male patient on the sixth day of illness within 48 hours of 
her exposure to oseltamivir. (Written patient consent was 
obtained under Review Board approval no. E09-230.) A 
sore throat, myalgia, redness of the right eye, and a mild 
fever with a productive cough had developed on the day 
she returned to Singapore from Hawaii. Eleven close con-
tacts, exposed before emergence of the mutant, were given 
oseltamivir prophylaxis on the patient’s fourth day of treat-
ment, and they remained well. By performing sequencing 
directly on 6 of her respiratory samples and on their viral 
isolates (online Technical Appendix, www.cdc.gov/EID/
content/16/10/1633-Techapp.pdf), we investigated the ori-
gin of this H275Y mutant (the second earliest sample of 
this mutation to be deposited in GenBank).
Only wild-type sequences were detected in samples 
collected on the day before, the day of, and 14 hours af-
ter initiation of oseltamivir therapy (online Technical Ap-
pendix Table 1). Similarly, only wild-type sequences were 
detected in 192 clones generated from a sample collected 
a few hours before initiation of oseltamivir. Pyrosequenc-
ing directly on clinical samples collected 38 and 45 hours 
after initiation of therapy showed 24% and 52% mutant se-
quences, respectively (Figure). The relative amount of vi-
rus detected, as determined by the strength of PCR results 
(online Technical Appendix Table 1), increased from days 
3 to 5 of illness by ≈1,000-fold. Oseltamivir treatment was 
initiated on day 4 of illness. On the same day, her maximum 
body temperature (38.8°C) was recorded, although no other 
signs or symptoms of clinical deterioration were observed. 
Her fever resolved on day 5 of illness, and she was allowed 
out of isolation on day 7 of illness.
When we compared the mutant drug-resistant isolate 
GN285 with the wild-type drug-sensitive isolate ON129, 
we found only 1 aa difference, the H275Y resistance-caus-
ing mutation in the neuraminidase gene, whereas a com-
parison of GN285 and ON129 with the reference strain A/
Texas/05/2009(H1N1) showed several mutations (online 
Technical Appendix Table 2). Mutation PB1 I435V, shared 
between GN285 and ON129, did not occur in any of the 
other 7 drug-resistant strains included in the analysis. The 
whole genome maximum likelihood tree (online Technical 
Appendix Figure 1) showed that the wild-type and resistant 
viruses isolated from this patient were more closely related 
to each other than to any other virus in the analysis. Nota-
bly, GN285 and ON129 clustered together in 376 of the 
500 bootstrap tests.
Conclusions
Our data indicate that oseltamivir resistance developed 
within 2 days. This time is similar to the interval for de-
velopment of resistance to adamantanes in subtype H3N2 
viruses when 30% of treated patients shed resistant, trans-
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Four cases of H275Y infection have been detected, with the 
use of sequencing, among 1,060 pandemic (H1N1) 2009 
isolates tested (0.47%) in Singapore since June 2009 (not 
including the case reported here). Only 1 case was found 
in a pretreatment sample; the other 3 were identiﬁ  ed after 
treatment. The emergence of H275Y might also be affected 
by the timing of therapy. In the case reported here, oselta-
mivir treatment was begun on day 4 of illness when viral 
titers were almost maximal, which is probably the stage of 
illness best suited to select for resistant mutants because the 
presence of mutations is likely to be greatest when replica-
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Figure. Pyrograms showing evolution of the H275Y mutation in pandemic (H1N1) 2009 virus, Singapore. A) May 29, sample 14 h after 
receiving oseltamivir shows 100% G. B) May 30, 38-h sample shows 76% G and 24% A. C) May 30, sample at 45 h  shows 48% G and 
52% A. D) May 30, virus isolated from 38-h sample is 100% A. The shaded area indicates the mutation site, showing the progressive 
loss of the third base, G, and its replacement by A. In panel A, all bases have peaks of equivalent height because each base is a singlet, 
except for the last peak, which is double the height and represents an A followed by another A, as in AA. In panel D, the G at the mutation 
site has disappeared and the signal of the next base, A, has doubled in amplitude, indicating the complete replacement of G by A. This 
reﬂ  ects replacement of the complementary base C by T in the viral template. The 3 bases that constitute aa 275 in the neuraminidase 
protein are underlined in panels A and D. In panel A, the sequence is 100% GTGATAA. In panel D, it is 100% GTAATAA. In panel A, the 
wild-type 5′-GTG-3′ is equivalent to 3′-CAC-5′ in its plus-strand RNA, which codes for histidine (H). Similarly, the mutant 5′-GTA-3′ in panel 
D is equivalent to 3′-CAT-5′, which codes for tyrosine (Y). Therefore, the pyrograms show a mutation from H to Y at position 275—the 
H275Y mutant.Oseltamivir-Resistant Pandemic (H1N1) 2009
tion is greatest. Notably, rates of H275Y are high, reach-
ing 13% (8) among immunocompromised groups in whom 
high viral titers might also be a contributory factor.
Pyrosequencing directly on clinical material allows the 
measurement of relative quantities of viral variants with-
out introducing errors inherent in viral culture, which is 
known to favor the growth of H275Y mutants (6). Pyrose-
quencing cannot exclude the presence of subpopulations 
of <5%–10%, but if small proportions of mutant virus had 
been present, they would have been detected in the culture 
of the sample collected 14 hours after exposure to oselta-
mivir; however, only wild-type sequences were detected. 
Similarly, only wild-type sequences were detected in 192 
clones derived directly from the sample collected a few 
hours before the ﬁ  rst dose of oseltamivir. The phylogenetic 
data show, at the amino acid and nucleotide level, that the 
resistant and sensitive isolates cluster together, apart from 
other viruses. These data support the hypothesis that the 
H275Y mutant arose de novo from the wild-type virus from 
the same patient.
The fact that the effects of oseltamivir are likely to be 
greatest in severe disease (9–11), but of modest beneﬁ  t in 
mild infections (12), has led to proposals for restricting the 
use of antiviral agents and the use of alternative antiviral 
agents and multidrug therapy to prevent the emergence of 
resistance (7,9) in severe cases. The proposed interventions 
may be of little consequence compared with the associa-
tion and co-selection of H275Y with other genetic determi-
nants. Although in isolation H275Y compromises seasonal 
inﬂ  uenza (H1N1) by reducing the amount of neuraminidase 
expressed on the cell surface, other mutations (R194G, 
V234M, and R222Q) may compensate and restore its ex-
pression to levels found in wild-type virus, without H275Y 
(13). This circumstance may explain the emergence and 
spread of H275Y in the absence of drug pressure in sea-
sonal inﬂ  uenza (H1N1), which increased from being neg-
ligible in 2007 to 95% in March 2009 (7) despite a low 
consumption of oseltamivir (14). More than 99% of all 
pandemic (H1N1) 2009 neuraminidases have G at posi-
tion 194, which corresponds to the R194G in seasonal in-
ﬂ  uenza (H1N1). However, the effects of mutations are not 
easily transferable among different inﬂ  uenza (H1N1) types 
and may need to be tested separately (online Technical 
Appendix).
The clinical effects of the spread of H275Y in seasonal 
inﬂ   uenza (H1N1) have been minimal because seasonal 
inﬂ  uenza (H1N1) now accounts for an insigniﬁ  cant pro-
portion of inﬂ  uenza (15). However, if H275Y mutants of 
pandemic (H1N1) 2009 emulate the expansion of resistant 
seasonal inﬂ  uenza (H1N1), the effect might be substantial 
because pandemic (H1N1) 2009 accounted for 90%–95% 
of circulating inﬂ   uenza A viruses in the Northern and 
Southern Hemispheres in late 2009 (15). We are speculat-
ing, however, because our laboratory data show that pan-
demic (H1N1) 2009 fell from 62% to 29% of 436 inﬂ  u-
enza cases from May 2010 to mid June 2010, Singapore’s 
main inﬂ  uenza season, whereas the presence of inﬂ  uenza 
(H3N2) has risen from 23% to 53% (inﬂ  uenza B accounts 
for 15%–20%). As the next inﬂ  uenza season in the South-
ern Hemisphere approaches, the relative mixture of sub-
type H3N2 and H1N1 viruses will be under scrutiny again, 
not only to predict “best bet” vaccine components but also 
to ascertain their associated resistance patterns. Whatever 
the epidemiologic data exhibit, clinicians should consider 
resistance when patients do not respond to treatment for 
pandemic (H1N1) 2009 because H275Y can emerge liter-
ally overnight, as the case reported here reminds us.
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